Related Experiment Video
Updated: Sep 28, 2026
Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
Published on: November 22, 2019
Differential expression of genes during TPA-induced differentiation of human prostatic cancer TSU-Pr1 cells
Toshihiro Suzuki1, Takahisa Shimizu, Kimiyoshi Satoh
1Department of Hygiene-Chemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Funagawara-Machi, Shinjuku-ku, Tokyo 162-0826, Japan.
Abstract:
We are interested in the possibility of a new prostate cancer therapy that would control tumor malignancy via induction of terminal cell differentiation. We previously reported that 12-O-tetra-decanoylphorbol-13-acetate (TPA) induces differentiation into cells with characteristics of microglia and decreases the malignant characteristics of human prostatic cancer TSU-Pr1 cells. To investigate the mechanism underlying differentiation of TSU-Pr1 cells, we attempted to identify genes expressed during differentiation using differential display. We identified four genes expressed differentially after TPA treatment. Levels of expression of two genes, human flavoprotein subunit of complex II and JKTBP, were downregulated by TPA, and expression of two genes, human golgin p245 and bcl-xL, was upregulated. Moreover, we found that the changes in expression of flavo-protein, JKTBP and bcl-xL induced by TPA were blocked by treatment with protein kinase C (PKC) or mitogen-activated protein (MAP) kinase inhibitors that prevent TPA-induced differentiation of TSU-Pr1 cells. These results suggest that the differential expression of these genes is associated with TPA-induced differentiation of TSU-Pr1 cells. We expect that understanding the roles of these genes during differentiation will provide for new approaches and therapeutic targets for treatment of prostate cancer.
Insights
This study explores new prostate cancer therapies by inducing cell differentiation. Researchers identified key genes, like bcl-xL, whose expression changes are crucial for this TPA-induced differentiation process.
Area of Science:
- Oncology
- Molecular Biology
- Cell Differentiation
Background:
- Prostate cancer malignancy may be controlled by inducing terminal cell differentiation.
- 12-O-tetra-decanoylphorbol-13-acetate (TPA) has previously been shown to induce differentiation in human prostatic cancer TSU-Pr1 cells, decreasing their malignant characteristics.
Purpose of the Study:
- To investigate the molecular mechanisms underlying TPA-induced differentiation of TSU-Pr1 cells.
- To identify genes whose expression is altered during this differentiation process.
- To explore potential therapeutic targets for prostate cancer treatment.
Main Methods:
- Differential display was used to identify genes expressed during TPA-induced differentiation of TSU-Pr1 cells.
- Quantitative analysis of gene expression levels (upregulation/downregulation) following TPA treatment.
- Inhibition studies using protein kinase C (PKC) and mitogen-activated protein (MAP) kinase inhibitors to assess their role in TPA-induced gene expression changes.
Main Results:
- Four genes showed differential expression after TPA treatment: human flavoprotein subunit of complex II and JKTBP were downregulated, while human golgin p245 and bcl-xL were upregulated.
- Changes in flavoprotein, JKTBP, and bcl-xL expression were blocked by PKC or MAP kinase inhibitors, indicating their involvement in the differentiation pathway.
- These gene expression changes are associated with TPA-induced differentiation of TSU-Pr1 cells.
Conclusions:
- The study identifies specific genes (flavoprotein, JKTBP, golgin p245, bcl-xL) differentially expressed during TPA-induced prostate cancer cell differentiation.
- The involvement of PKC and MAP kinase pathways in regulating these gene expression changes highlights their significance in the differentiation process.
- Understanding the roles of these identified genes may lead to novel therapeutic strategies and targets for prostate cancer treatment.
